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Abstract
Chronic obstructive pulmonary disease (COPD) is a major public health problem with increasing prevalence worldwide. The
primary aim of this study was to identify genes and gene ontologies associated with COPD severity. Gene expression
profiling was performed on total RNA extracted from lung tissue of 18 former smokers with COPD. Class comparison
analysis on mild (n=9, FEV1 80–110% predicted) and moderate (n=9, FEV1 50–60% predicted) COPD patients identified 46
differentially expressed genes (p,0.01), of which 14 genes were technically confirmed by quantitative real-time-PCR.
Biological replication in an independent test set of 58 lung samples confirmed the altered expression of ten genes with
increasing COPD severity, with eight of these genes (NNMT, THBS1, HLA-DPB1, IGHD, ETS2, ELF1, PTGDS and CYRBD1) being
differentially expressed by greater than 1.8 fold between mild and moderate COPD, identifying these as candidate
determinants of COPD severity. These genes belonged to ontologies potentially implicated in COPD including angiogenesis,
cell migration, proliferation and apoptosis. Our secondary aim was to identify gene ontologies common to airway
obstruction, indicated by impaired FEV1 and KCO. Using gene ontology enrichment analysis we have identified relevant
biological and molecular processes including regulation of cell-matrix adhesion, leukocyte activation, cell and substrate
adhesion, cell adhesion, angiogenesis, cell activation that are enriched among genes involved in airflow obstruction.
Exploring the functional significance of these genes and their gene ontologies will provide clues to molecular changes
involved in severity of COPD, which could be developed as targets for therapy or biomarkers for early diagnosis.
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Introduction
COPD is predicted to become the fifth most common cause of
disease burden worldwide by 2020 [1]. COPD contributes a huge
economic burden; estimates from Australia indicate over US $9
billion in health care costs annually. COPD is often under-
diagnosed, as it is not usually recognized until its severity is
moderately advanced, when preventive measures are too late to
prevent severe disease [2]. Understanding the pathogenesis of
COPD severity, especially in the earlier mild and moderate stages
of COPD, would greatly enhance diagnostic and therapeutic
strategies for this deadly disease.
Because of the complexity of COPD pathophysiology in the
lungs, measuring COPD severity comprehensively is challenging.
The different compartments of the tracheobronchial tree (large
airways, small airways (bronchioles) and alveoli) contribute
differently and specifically to the pathophysiological changes of
COPD. FEV1 is a physiological measure of airway obstruction
particularly in the small airways [3], but fails to correlate with the
extent of emphysema severity in the parenchyma [4]. Gas transfer
(KCO) correlates with emphysema severity (alveolar destruction in
the lung parenchyma), and emphysema contributes to airflow
obstruction due to loss of elastic recoil; however, KCO does not
correlate strongly with FEV1 in COPD. Additionally, the
bronchioles and parenchyma demonstrate different patterns of
gene expression in COPD [5]. Clearly, pathophysiological studies
of markers of COPD severity should assess spirometric indicators
of airflow obstruction (reduced FEV1 and FEV1/VC), as well as
impairment of gas transfer (KCO) as an indicator of emphysema.
Microarrays are useful high-throughput tools for studying the
expression of multiple genes simultaneously, as markers of disease
pathogenesis. Microarrays have been previously used to profile
biospecimens from COPD patients to identify characteristic gene
expression patterns associated with the presence of COPD, its
severity and subphenotypes. Several studies have addressed gene
expression in specific cell types [6,7,8]. Whilst studying specific cell
types is important, multiple cell responses are likely to drive the
severity of COPD. Only two previous studies by Wang et al [9] and
Bhattacharya et al [10], have used lung tissues to profile COPD
severity. The former study included limited number of patients in
the more severe subgroups, with 21 GOLD stage 0, 9 GOLD stage
I, 10 GOLD stage II and only 3 GOLD stage III patients. The
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25% and 75% of forced expiratory volume (FEF25–75%). The latter
study profiles 56 lung tissues, but compared normal cases to
COPD patients with any degree of severity (GOLD 0-IV).
Similarly, profiles linked to emphysema has been reported by
Spira et al [11], Golpon et al [12] and Savarimuthu et al [13].
We primarily sought to identify disease-associated genes and
gene ontologies related to airflow obstruction. To better
understand the pathobiology of disease severity in COPD, we
searched for genes differentially expressed in lung tissue using
microarrays between mild (GOLD Stage I) and moderate (GOLD
Stage II) COPD patients, stratifying them by FEV1. These genes
could provide clues to molecular changes involved in the severity
of COPD that could potentially be developed as targets for
therapy or biomarkers for early diagnosis. Secondarily, we sought
to identify gene ontologies common to both airflow obstruction,
indicated by reduced FEV1, and emphysema, indicated by KCO.
In a complex disease such as COPD, it is probable that groups of
genes rather than single genes are involved in disease development
and severity. To further explore common ontologies and
pathways, differentially expressed genes were collated with those
previously identified as associated with COPD severity [4–9].
Methods
Sample selection, sample processing and microarray
experiments
Patients with varying severity of COPD undergoing curative
resection for lung cancer at The Prince Charles Hospital,
Brisbane, provided written informed consent for the collection
and study of samples of macroscopically normal non-tumour lung.
The study was approved by the institutional ethics committees of
The Prince Charles Hospital (TPCH) and The University of
Queensland.
Inclusion and exclusion criteria for the COPD patients were as
previously published by our laboratory [13]. Nine patients with
mild COPD who had post-bronchodilator FEV1/VC,0.7 and
FEV1.80% predicted (GOLD Stage I) were compared with nine
patients with moderate COPD who had post-bronchodilator
FEV1/VC,0.7 and FEV1 measurements between 50 and 60%
predicted (within GOLD Stage II). To ensure a distinct separation
of mild and moderate COPD severity, patients with FEV1 between
60 and 80% predicted were not included in the training set, in
order to polarize the comparison groups. Spirometry was
performed as described previously [15] and conformed to standard
guidelines [16,17].
Sample processing and microarray experiments were as previ-
ously described [13,14]. Briefly, twenty nanograms of total RNA
was isolated from lung tissue, cleaned, quality evaluated, and
quantified using TRIzol (Invitrogen Corporation, Carlsbad, CA,
USA), Qiagen RNeasy mini kit (Qiagen, Hilden, Germany) and
Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA)
respectively. The study design for microarray experiments con-
formed to MIAME guidelines guidelines (http://www.mged.org/
Workgroups/MIAME/miame_checklist.html). Test lung RNA and
commercial universal reference (RNA Stratagene, La Jolla, CA,
USA) was reverse transcribed to cDNA along with. Lung cDNA
and reference cDNA were labeled with Cy5 and Cy3 dyes
respectively (Amersham/GE Healthcare, Buckinghamshire, En-
gland) and then co-hybridized on an Operon V2.0 12k element
microarray chip (http://www.operon.com). The slides were washed
and scanned to obtain raw images which were combined and
filtered in Imagene V5.1 (BioDiscovery, Inc., El Segundo, CA,
USA). The samples were normalized using Lowess and probes with
missing values in 50% or more samples were removed from the
analysis in Avadis V4.3 (Strand Genomics, Bangalore, India). All
normalized data has been deposited in the NCBI Gene Expression
Omnibus (GEO) public repository (http://www.ncbi.nlm.nih.gov/
geo) and can be accessed through the accession number GSE17770.
Log ratio variation gene filtration was performed in BRB-Array
Tools V3.8 (developed by Dr Richard Simon and Amy Peng Lam,
freely accessible online at http://linus.nci.nih.gov/BRB-Array-
Tools.html), to only include probes that varied significantly
(P,1.0E-6) from the median of all samples.
Data analysis
Gene discovery and validation. Class comparison analysis
using an independent t-test was performed in BRB-ArrayTools to
find genes differentially expressed between mild and moderate
COPD patients at p,0.01. Genes identified were technically
validated using qRT-PCR with primers designed to amplify the
same transcripts represented on the microarray platform.
Technical variability in amount of mRNA per sample was
normalized to the universally expressed housekeeping genes, 18s
rRNA, HGS and ACTN4 [18]. The average gene expression for
cases with moderate COPD (GOLD Stage II) divided by the
arithmetic average of expression in cases with mild COPD
(GOLD Stage I) was calculated as the fold change. Genes that
displayed concordant increase or decrease in fold change as
measured by both microarray and qRT-PCR were determined to
be technically validated.
Genes that were technically validated were selected for
biological validation in an independent set of 58 lung samples
from the TPCH tissue bank; these samples were selected on the
basis of the patients’ FEV1 and FVC measurements. No exclusions
for smoking status, cumulative pack years of smoking, histology,
steroid use, or comorbidity were applied to the test set, aiming for
wide inclusion in the test set to confirm generalizability. Total
RNA from the non-tumour lung samples was extracted using
TRIzol and reverse transcribed to cDNA using Superscript III
(Invitrogen). Genes were quantitated using qRT-PCR and
normalized to housekeepers as described above. Quantitative
expression of each gene was calculated using Pfaffl’s method [19].
The change in fold expression was calculated between patients
with mild and moderate COPD in the test set. Genes with
concordant fold change in the test and training set and greater
than 1.8 fold differences in the test set were determined to be
biologically validated.
Biological validation of candidate genes in published
datasets. External validation in public gene expression
microarray datasets was performed to ensure that differentially
expressed genes were authentic candidates, which were not
overfitted to a particular cohort. The Bhattacharya et al [10] and
Wang et al [9] datasets were downloaded from GEO Omnibus
(GSE8581 and GSE8500, repectively using array platforms,
Affymetrix Human U133Plus 2.0 and Rosetta hu25k
respectively). Chip comparer (http://tenero.duhs.duke.edu/
genearray/perl/chip/chipcomparer.pl) was used to find probes
represented on Affymetrix (46,000 probes) or Rosetta (21,000
probes) and the Operon V2.0 platform. Normalized signals were
imported into BRB-Array Tools and only signals that were called
present were used in the analysis. Leave one out cross validation
(LOOCV) analysis was performed to test the prediction accuracy
of our candidate genes in other datasets.
Gene Enrichment and Pathway analysis. GOEast (Gene
Ontology Enrichment Analysis Software Toolkit) was used to
identify gene ontologies enriched significantly (p,0.05) between
the various studies [20]. The ontologies of gene candidates
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[10] and this study (henceforth refered to as TPCH-FEV1) were
individually analysed and overlayed to find commonality between
their gene ontologies. Additionally, we used the above method to
identify gene ontologies common to severity of COPD (airflow
obstruction) and emphysema, indicated by impaired FEV1
(TPCH-FEV1, and KCO, respectively. Ingenuity Pathway
Analysis (IPA) was performed to find direct relationships
between candidate genes.
Results
Demographics
Characteristics of patientsincluded inthe test and independent set
are listed in Table 1. The training samples were classified according
to GOLD classification into mild COPD (Stage I) (n=9, median
FEV1 94.7% predicted, range 80–110% predicted) and moderate
COPD (Stage II) (n=9, median FEV1 52.6% predicted, range 50–
60% predicted). All subjects included in the study were Caucasians.
The training set consisted of former smokers, with greater than 20
pack year smoking history who had quit at least 10 months prior to
surgery. The subjects did not have evidence of obstructive
pneumonitis due to tumor obstruction and were not taking any
inhaled or oral steroids. The test set samples consisted of patients
with mild COPD (n=39, median FEV1 91% predicted, range 80–
135% predicted) and moderate COPD (n=19, median FEV1 54%
predicted, range 30–60% predicted). The test group included
current and former smokers with a 1 to 224 pack year history.
Gene discovery and Validation
After initial filtering for poor quality spots and normalization,
20,274 probes representing 12,178 known genes remained. After
filtering, 2,155 genes were identified as having significant variation
in expression (p,1.0E-6) compared to the average expression of
per gene in all samples. Unsupervised hierarchical clustering of the
filtered genelist revealed no obvious association of the genes with
the age, gender or smoking history of the samples. A t-test
identified 46 probes representing 46 genes significantly different in
expression (p,0.01) between lungs from patients with mild and
moderate COPD (Table S1). These 46 genes were 67% accurate
in classifying mild (GOLD stage I) and moderate (GOLD stage II)
COPD using LOOCV with diagonal linear discriminate algorithm
in the training samples. Sixteen of the 46 genes had incomplete
sequence complementarity to a corresponding gene using BLAST
searches in Ensembl genome browser based on the human build
17 and were excluded from further analysis, leaving 30 probes for
technical validation. Fourteen genes demonstrated consistent
changes in gene expression (concordant direction of fold-change)
by qRT-PCR when comparing mild and moderate COPD
samples. The reduced gene list was 94% accurate (90% sensitive,
100% specific) in classifying the COPD severity groups in the
training samples.
Biological validation of the 14 candidate genes was performed
in an independent test set of 58 COPD patients selected from the
TPCH tissue bank. The difference in average gene expression
between mild and moderate COPD patients (based on FEV1) was
calculated. Genes with concordant changes in direction with the
microarray data and the training set were identified as candidates.
The magnitude of fold difference in expression between COPD
groups, based on FEV1, was greater than 1.8 for eight of these
genes (NNMT, THBS1, HLA-DPB1, IGHD, ETS2, ELF1, PTGDS
and CYRBD1) (Figure 1A and 1B (b&c)). These genes were
therefore considered candidates for a functional role in COPD
severity.
Biological validation of candidate genes in Bhattacharya
and Wang datasets
The ability of these eight genes to predict COPD severity based
on FEV1 in two public datasets was tested using class prediction in
BRB-ArrayTools V3.8. All eight genes were represented in the
Bhattacharya et al dataset that used an Affymetrix platform and
seven were represented in the Wang et al dataset that used a
Rosetta platform. The candidate genes were 55% accurate (61%
specificity and 46% sensitivity) and 62% accurate (63% specificity
and 57% sensitivity) in classifying the Bhattacharya et al and Wang
et al datasets respectively. Seven of the eight genes demonstrated a
concordant change in expression between mild and moderate
COPD patients in at least one of the two public datatsets.
Additonally, the change in direction of three genes (THBS1,
NNMT and HLA-DPB1) were consistent in all three studies
(Figure S1).
Gene Enrichment and Pathway analysis. Gene
Enrichment analysis and pathway analysis were performed to
identify gene ontologies and functions that are commonly
dysregulated in relation to COPD in published gene expression
datasets. A summary of the gene ontologies enriched in TPCH-
FEV1 study as well as the published studies where FEV1 or KCO
(or DLCO) was used to stratify COPD patients is shown in Table
S2 and Figures S2a and S2b. Several ontologies were found to be
commonly enriched in gene profiles identified by at least two of the
four COPD studies that used only FEV1 to classify COPD severity
(Ning, Wang, Bhattacharya and this study), namely, chronic
inflammatory response, negative regulation of fibrinolysis,
regulation of fibroblast growth factor receptor signaling pathway,
sprouting angiogenesis, regulation of macrophage activation,
positive and negative regulation of blood vessel endothelial cell
migration and regulation of protein processing.
Table 1. Demographics of COPD patients in the TPCH
training and test sets.
Training Set Test Set
GOLD
Stage I
GOLD
Stage II
GOLD
Stage I
GOLD
Stage II
n9 9 3 9 1 9
Age
Gender
6968
M: 7
F: 2
7066
M: 7
F: 2
6569
M: 29
F: 10
65610
M: 15
F: 4
FEV1%
predicted
94675 4 639 4 611 5268
FEV1/VC 0.6060.03 0.5060.05 0.6060.15 0.5260.08
Pack years
# 66 [24–135] 78 [40–158] Current: 60
Former: 39
Current: 55
Former: 53
Smoking
Status
Former Former 16 Current
23 Former
3 Current
16 Former
Site of
Lobectomy*
1-LLL
2-LUL
1-RL
1-RLL
4-RUL
5-RLL
1-RML
3-RUL
5-LLL
7-LUL
5-RLL
2-RML
16-RUL
4-LL
5-LLL
6-LUL
1-RLL
2-RML
4-RUL
1-LL
Values are shown in mean 6 SD where indicated except
# where values are shown
in Median [Min-Max].
*LL- Left Lung, LLL- Left Lower Lobe, LUL- Left Upper Lobe, RL -Right Lung, RLL-
Right Lower Lobe, RUL- Right Upper Lobe, RML- Right Middle Lobe. FEV1- forced
expired volume in one second, VC- vital capacity (ventilatory measurement).
doi:10.1371/journal.pone.0017442.t001
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profiles of FEV1 or KCO (or DLCO), namely, regulation of focal
adhesion formation, regulation of oxygen and reactive oxygen
species metabolic process, negative regulation of focal adhesion
formation, prostaglandin biosynthetic process, positive regulation of
leukocyte chemotaxis, and apoptotic cell clearance. Gene ontologies
enriched in each of the published studies, Ning [6], Wang [9],
Bhattacharya [10], Spira [11], Golpon [12] and our previous study
(TPCH-KCO), Savarimuthu [13], as well as the TPCH-FEV1
study, are listed in Tables S3, S4, S5, S6, S7, S8 and S9.
Pathway analysis using IPA showed direct associations between
gene candidates (THBS1, PTGDS, ELF1 and ETS2) and genes
involved in cell cycle regulation (tumour protein 53, (TP53) and
JUN), apoptosis (insulin-like growth factor binding protein,
IGFBP4), transcription (SP1), mucin production (MUC2) and
DNA repair (excision repair cross complement, ERCC1) (Figure 2).
Discussion
COPD is a complex chronic lung disease characterised by
irreversible airflow limitation in the lung, as clinically diagnosed by
spirometric measurement using FEV1, and by lung parenchymal
destruction, as clinically diagnosed by gas transfer measurement
using KCO, in addition to radiological imaging. We previously
reported on seven candidate genes involved in emphysema
severity, diagnosed by reduced KCO [13], which were capable
of predicting independent test sets with high accuracy [13,14].
Here, we have investigated the lung tissue of COPD patients, and
stratified patients by FEV1. We have identified 46 genes involved
in COPD severity; these genes were differentially expressed
between mild and moderate COPD (GOLD class I and II
severities). Technical and biological validation found eight genes
with reproducible differences in mRNA expression between the
mild and moderate COPD groups based on their FEV1. These
genes are therefore potentially associated with COPD severity.
Several studies have used expression profiling to characterise
genes involved in COPD of any phenotype (especially emphysema)
[6,7,8,9,10], yet only two have specifically explored the gene
expression in lung tissues of COPD patients stratified by FEV1
[9,10]. The first of the studies [9] identified a 203 transcipt gene
panel associated with the various stages of COPD (GOLD 0-III);
however the severe stage comprised of only three cases. The
second study [10] identified a set of 65 transcripts that were
differentially expressed when comparing normal and severe
Figure 1. Technical Validation of eight candidate genes in the training and test set using qRT-PCR. A) Comparison of mRNA expression
differences between mild (GOLD I) and moderate (GOLD II) COPD patients in the candidate eight genes measured by qRT-PCR and gene expression
microarrays. B) Graph of candidate genes in TPCH training set (b) (n=30) and TPCH test set (c) (n=63). The figures 1b&c show the median gene
expression of the mild (m) and moderate (N) emphysema.
doi:10.1371/journal.pone.0017442.g001
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an independent dataset published by Spira et al [11] with 97%
accuracy. We identified eight genes capable of classifying mild
(GOLD I) and moderate (GOLD II) COPD patients in the
TPCH-training set, TPCH-test set and in external validation
datasets [9,10].
A strength of our study is validation of results using a number of
methods: technical validation (validation of technique) through
replication of the microarray gene expression findings using qPCR
on the same samples of the training set; biological validation in an
independent test set of samples from the same tissue bank (from
our hospital); biological validation in independent external
training set from other datasets (publicly available from other
centres). Applying these methods we identified candidate genes
that are involved in molecular, biological or cellular functions that
are potentially associated with COPD pathogenesis. Gene names
and their function are summarized in Table 2. NNMT has been
previously described to be involved in COPD [21,22]. NNMT is
overexpressed in quadriceps muscles of COPD patients and likely
to contribute to cell proliferation and migration. The expression of
NNMT is significantly triggered by IL6, TNFa and TGFb [21].
We found expression of NNMT to inversely correlate with FEV1,
a result which is similar to previously published studies. THBS1
activates TGFb and matrix metalloproteinases (MMP) [9],
mediates cell-cell and cell-matrix interactions, and is involved in
angiogenesis, proliferation and platelet aggregation. THBS1 has
been previously identified in COPD lung and its expression
validated by Wang et al [11] using immunohistochemistry. These
mechanisms are key indicators of inflammation and hypoxia in
COPD patients. CYBRD1 is as an iron (Fe+) reductase in the
airway epithelial cells, an important mechanism inducing
hyperoxia and oxidative stress in the lung [23]. PTGDS [24],
IGHD [25] and HLA-DPB1 regulate host immunity and inflam-
mation. Spira et al found PTGDS expression to negatively correlate
(r=0.63) with FEV1 post-bronchodilator (% predicted) [11]. Two
of the candidate genes from this study, ETS2 and ELF1, are
Figure 2. Ingenuity Pathway Analysis (IPA) on the eight biologically validated candidate genes. Bold lines indicates direct link, dotted
lines indicate indirect link. Orange nodes indicate input genes into the pathway analysis and the different symbols indicate gene functions.
doi:10.1371/journal.pone.0017442.g002
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development, cell senescence and death and tumourigenesis.
ETS2 is related to important COPD pathways through molecules
such as HRAS, HDAC2, EGFR and RAF1. ELF1 interacts with
known COPD genes, NFkB1, NFYB, RB1, and SP1. ELF1 acts
both as an enhancer (increases cytokine production), and repre-
ssor (negative regulator of T-cell receptor mediated signaling
pathway). Therefore, integration of gene ontology and recent
literature shows that the candidate genes identified in our study are
involved in processes that are potentially associated with COPD
pathogenesis.
Results of the TPCH-FEV1 study were compared with
previously published gene expression profiling studies of COPD
(Ning et al [6], Wang et al [9] and Bhattacharya et al [10]) to
determine if the same candidate genes were discovered by others.
These studies reported 327, 203 and 84 respective candidates to be
involved in COPD severity. Three of the eight candidates we
identified were reported by at least one of the three previous
studies: THBS1 (Wang et al), IGHD1 (Bhattacharya et al) and
CYBRD1 (Ning et al) and they were similarly up-regulated in
moderate/severe COPD, as observed in this study. Although there
was not much overlap between individual genes, there was a
significant enrichment of common gene ontologies [26,27]. This
strengthens the association of our candidates with FEV1 predicted
COPD severity. Additionally, class prediction (LOOCV) analysis
provided an unbiased estimate of the classification performance of
the eight genes in independant samples with a classification
accuracy of 55% in Bhattacharya et al and 62% in Wang et al. This
shows that the genes are not over fitted to one study and therefore,
they pass a critical validation step by predicting independent test
samples that are biologically related with improved accuracy.
The eight candidate genes were significantly enriched for
several gene ontologies (Table S3) including T-cell receptor
signaling, extracellular matrix binding, positive regulation of
phosphorylation cell-substrate adhesion cell adhesion and activa-
tion of MAPK activity. In order to identify gene ontologies
consistently enriched in published expression profiling studies of
COPD severity we compared the current study with three other
studies that classifies COPD severity by FEV1 [6,9,10]. Negative
regulation of cell-substrate adhesion, endothelial cell migration &
proliferation, focal adhesion formation, angiogenesis, blood vessel
and vasculature development, blood vessel morphogenesis,
regulation of blood vessel, response to oxygen levels, and
regulation of protein processing were common to atleast three
studies (Ning et al and Wang et al and this study) with none
enriched in all four studies. Only two ontologies, prostaglandin
metabolic process and prostanoid metabolic process were common
with the Bhattacharya et al gene set.
In comparing the shortlisted 46 candidate gene lists associated
with distinguishing mild from moderate COPD classified by FEV1
(TPCH-FEV1) to the study where seven genes associated with
distinguishing mild from moderate emphysema classified by KCO
(TPCH-KCO) [13], only one gene, COL6A3 (collagen, type VI,
alpha 3) was common to both phenotypes. Although COL6A3 was
strongly associated with reduced KCO, it failed to validate
biologically in the independent samples when classified by FEV1.
Minimum overlap in genes may indicate the pathogenesis
regulating FEV1 and KCO impairment involves different
molecular mechanisms. Interestingly, the study by Bhattacharya
and colleagues [10] identified 220 genes, of which a subset of 40
transcripts could distinguish lung tissues with mild or no
emphysema from severe emphysema in a previously published
gene expression study [11]. So although there is no commonality
on a gene by gene basis which is not uncommon in microarray and
replication studies [14,26,28], similar molecular mechanisms and
gene ontologies are enriched between the phenotypes of impaired
FEV1 and KCO (Figure S2b).
The lack of histological characterisation of the tissues arrayed
could impact on the levels of expression due to the heterogeneity of
the cells between tissues. However a recent study showed that
differences in tissue content did not alter the relationship between
lung function and expression [9]. Spirometric measurements of
FEV1 rather than histology have been used previously to classify
severity in COPD patients. In the international clinical guidelines,
lung function parameters are used to diagnose the presence of
COPD. FEV1% predicted is currently the major physiological
indicator used clinically, in the presence of FEV1/FVC,0.70, to
classify COPD disease severity, using the GOLD severity stages.
Hence we used FEV1% predicted as the clinical physiological
indicator and relevant phenotype to identify genes differentially
expressed between mild and moderate COPD severities. False
discovery rate (FDR) threshold was not specified to this discovery
set. However, we used additional validation techniques (technical
and biological) to validate candidate genes from the initial training
set, to add robustness to the prioritisation of these genes.
In summary, eight robust candidate genes have been identified
and validated, based on mRNA expression in lung tissue, that are
potentially involved in COPD severity. These genes deserve
further investigation to better understand their mechanistic
association with COPD and explore their role as potential
therapeutic targets or diagnostic markers. Future directions
include testing gene function in in vitro models and analyzing
Table 2. List of the eight candidate genes and their function.
Gene Symbol Gene description Function
NNMT Nicotinamide N-methyltransferase Methylating agent, regulating gene expression
THBS1 Thrombospondin 1 Cell-cell and cell-matrix interactions/angiogenesis, tumorigenesis
and platelet aggregation
IGHD Immunoglobulin heavy delta chain Apoptosis/survival of B-cell chronic lymphocytic leukemia
HLA-DPB1 major histocompatability complex, class II, DP Beta 1 Antigen presenting cells that regulate the immune system
PTGDS Prostaglandin D2 synthase Positive regulator of apoptosis
CYBRD1 Cytochrome B-Reductase 1 Hyperoxia/oxidative stress
ETS2 Erythroblastosis virus E26 oncogene homologue 2 Stem cell development, cell senescence and death and tumorigenesis
ELF1 E74 like factor 1 Cytokine production/negative regulator of T-cell receptor
mediated signaling pathway
doi:10.1371/journal.pone.0017442.t002
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smokers e.g. mutation and microRNA regulation.
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